Sam Neill kicks cancer in the cells!
- Adam Spencer
- 1 day ago
- 4 min read
Hollywood legend Sam Neill is cancer-free after a CAR T-cell trial. Here's the beginner's guide to the"living drug" that pulled him back from the brink.
He outran a velociraptor AND lymphoma!
Sam Neill is perhaps best known as Jurassic Park's Dr Alan Grant.
Well our favourite honorary Aussie has delivered one of his great performances.
Strictly not all of him, but his T-cells.
These amazing parts of our immune system, which Aussie Peter Doherty helped us understand, winning a share of the 1996 Nobel for his work on them, are a cancer fighting unit already in your blood supply, just waiting to be called into action.
Let's find out about the ‘magic trick’ that saw them summoned. It's one of the great stories of modern science.
The final curtain?
Things were looking grim for Neill.
After five years with stage-three angioimmunoblastic T-cell lymphoma, which sucks about as bad as the name suggests it would, after chemo stopped working, after he reckoned he was "on the way out", a recent scan came back clean.
No detectable cancer.
His next plan?
"It's time I did another movie." — Sam Neill.
CAR T-cell therapy has been used for several years to fight blood cancers — but for T-cell lymphomas like Sam's, this is genuinely cutting-edge stuff.
Rather than relying only on chemotherapy or radiation, doctors took Neill's own immune cells out, reprogrammed them in a lab, and put them back to do the job they were meant to do.
The living drug as it is called, doesn’t always work, but when it does it is incredible. Here's how.
Outsmarting the big C.
T cells circulate through your blood and tissues looking for trouble. They recognise dodgy cells by the proteins (called antigens) studded on their surfaces. When a T cell spots something it doesn't like, it latches on and kills it.
The trouble is, cancer cells are sneaky. They can wear antigens that look benign, or disguise and reduce these signals, so your T cells stroll right past.
CAR T-cell therapy makes your T cells stop, take a breath, and get some serious whoop on.
Leukapheresic bark.
So exactly what goes down?
Scientists collect the patient's T cells through a process called leukapheresis. Blood goes out through a needle, a machine spins out the white blood cells, and the rest goes back in.
The harvested T cells are shipped to a specialised lab, where a virus is used to insert a new gene. That gene codes for a chimeric antigen receptor — the "CAR" in CAR T — a custom-built grappling hook that locks onto a protein found mainly on the patient's cancer cells.
The word “chimeric” is the giveaway. In Greek mythology, the chimera was a beast stitched together from a lion, goat and snake. These receptors are similarly stitched together. Strands of antibody glued to fragments of T-cell signalling machinery, creating a Frankenstein protein that doesn’t exist in nature. Pure bioengineering.
The hunt for red oncology.
Once the gene is in, the modified T cells multiply in the lab until there are hundreds of millions, sometimes billions of them. The whole manufacturing process takes around three to four weeks.
Meanwhile, the patient gets a short course of chemotherapy — not to kill cancer this time, but to clear space in the immune system so the new cells have room to expand once they're back.
Then the CAR T cells drip back in through an IV. An infusion that takes anywhere from five minutes to over an hour, after which it is game on.
What comes next is a hunt. The engineered cells circulate, and every time their CAR locks onto a cancer cell wearing the matching antigen, they kill it and then become activated, multiplying as they go.
"There is no question that using a patient's own immune system to fight cancer is one of the major medical breakthroughs of the 21st century." — Dr Ran Reshef, clinical lead CAR T-Cell Program, NewYork-Presbyterian/Columbia.
Unlike chemo, which leaves your body within days, CAR T cells can persist for months or years in some patients, standing watch. That's why oncologists call it a living drug: the medicine reproduces itself.
The hard cell.
This is by no means a perfect miracle cure.
Response rates vary widely. The impact is strong in some blood cancers, modest or non-existent in others. Solid tumours like breast or lung cancer have proven much harder. In those cases the cancer cells don't wave the same neat antigen flag, and finding targets without harming healthy tissue is a real challenge.
There are also side effects, including body-wide inflammation and reactions that can cross into the brain. Most can be treated with drugs, and patients are kept under close monitoring for days to a couple of weeks after infusion.
But the incredible success in patients like Neill only empowers researchers to ask: what can we do to expand the range of this incredible treatment?
Why Neill is making noise.
Like so many of these amazing breakthrough therapies, CAR T-cell therapy is not cheap.
The private cost can exceed A$600,000 per patient if you cannot get onto a clinical trial, which Neill was lucky enough to do.
This raises a range of complex ethical and economic questions, but Neill is using his profile to advocate for more research and more funded access.
That gets a standing ovation from me.
Hey, I'm also on Substack.
Comments